Arcturus Therapeutics’ (ARCT) “Buy” Rating Reaffirmed at HC Wainwright

Arcturus Therapeutics (NASDAQ:ARCT)‘s stock had its “buy” rating restated by HC Wainwright in a report released on Tuesday,Benzinga reports. They presently have a $63.00 target price on the biotechnology company’s stock. HC Wainwright’s price objective would indicate a potential upside of 230.36% from the company’s previous close.

Separately, Cantor Fitzgerald restated an “overweight” rating on shares of Arcturus Therapeutics in a research report on Monday, December 16th. Six analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $66.75.

Arcturus Therapeutics Stock Performance

Shares of ARCT opened at $19.07 on Tuesday. Arcturus Therapeutics has a 1 year low of $14.30 and a 1 year high of $45.00. The firm has a fifty day moving average of $17.56 and a 200-day moving average of $20.26. The company has a market cap of $516.55 million, a price-to-earnings ratio of -8.59 and a beta of 2.63.

Arcturus Therapeutics (NASDAQ:ARCT) last posted its earnings results on Thursday, November 7th. The biotechnology company reported ($0.26) EPS for the quarter, topping the consensus estimate of ($0.70) by $0.44. The firm had revenue of $41.67 million during the quarter, compared to analysts’ expectations of $49.16 million. Arcturus Therapeutics had a negative net margin of 36.39% and a negative return on equity of 22.39%. During the same quarter in the prior year, the firm earned ($0.61) EPS. Analysts predict that Arcturus Therapeutics will post -2.31 EPS for the current year.

Insider Activity

In other news, COO Pad Chivukula sold 12,000 shares of the company’s stock in a transaction on Tuesday, October 15th. The stock was sold at an average price of $20.76, for a total value of $249,120.00. Following the completion of the sale, the chief operating officer now owns 435,334 shares in the company, valued at $9,037,533.84. This represents a 2.68 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Insiders own 15.30% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of ARCT. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in shares of Arcturus Therapeutics by 10.8% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 8,694 shares of the biotechnology company’s stock valued at $202,000 after purchasing an additional 846 shares during the period. nVerses Capital LLC purchased a new stake in Arcturus Therapeutics during the third quarter valued at about $42,000. China Universal Asset Management Co. Ltd. boosted its holdings in shares of Arcturus Therapeutics by 64.4% in the third quarter. China Universal Asset Management Co. Ltd. now owns 5,201 shares of the biotechnology company’s stock worth $121,000 after buying an additional 2,038 shares during the period. Nordea Investment Management AB increased its position in shares of Arcturus Therapeutics by 3.7% in the fourth quarter. Nordea Investment Management AB now owns 65,778 shares of the biotechnology company’s stock worth $1,097,000 after acquiring an additional 2,335 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. raised its holdings in shares of Arcturus Therapeutics by 1.7% during the third quarter. Charles Schwab Investment Management Inc. now owns 197,622 shares of the biotechnology company’s stock valued at $4,587,000 after acquiring an additional 3,224 shares during the period. Institutional investors own 94.54% of the company’s stock.

About Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.